Replies to post #24313 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT +2% on JNJ’s strong results in medical-device segment (sales +8% YoY). ABT reports 3Q21 results tomorrow morning.

[DewDiligence]

ABT 3Q21 Results by Business Segment

  
                  %Corp      YoY Growth   
 Segment          Sales   (const currency)  
 Medical devices*  33%       +13%    
 Diagnostics       36%       +47%    
 Nutrition         19%        +9%    
 Drugs†            12%       +15% 

3Q21 COVID-19 diagnostics sales were $1.9B, 49% of total 3Q21 diagnostics sales.

60% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.